QurCan Therapeutics (formerly Nanology Labs)

www.qurcan.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
QurCan Therapeutics is fostering scientific creativity and pioneering a proprietary nanoparticle drug delivery technology called TERP to accelerate ​advanced nanomedicine-based therapeutics.

Related news

Entrepreneurs from Ontario’s Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations

April 8, 2019 – FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs. Read More

FACIT leads seed round in Nanology Labs

May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund. Read More

FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund

January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.